David Cunningham

Summary

Affiliation: Royal Marsden Hospital
Country: UK

Publications

  1. ncbi request reprint Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer
    Ian Chau
    Department of Medicine, Royal Marsden Hospital, London, United Kingdom
    J Clin Oncol 24:668-74. 2006
  2. doi request reprint Capecitabine and oxaliplatin for advanced esophagogastric cancer
    David Cunningham
    Royal Marsden Hospital National Health Service Foundation Trust, Surrey and London, United Kingdom
    N Engl J Med 358:36-46. 2008
  3. doi request reprint Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer
    Naureen Starling
    Department of Medicine, Royal Marsden Hospital, Downs Rd, Sutton, Surrey SM2 5PT, United Kingdom
    J Clin Oncol 27:5499-505. 2009
  4. doi request reprint Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial
    Yu Jo Chua
    Department of Medicine, Royal Marsden Hospital, Sutton, Surrey, UK
    Lancet Oncol 11:241-8. 2010
  5. pmc Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial
    Tom Waddell
    The Royal Marsden NHS Foundation Trust, London and Surrey, UK
    Lancet Oncol 14:481-9. 2013
  6. pmc Survival from cancer of the oesophagus in England and Wales up to 2001
    S Rao
    Department of Medicine, Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, UK
    Br J Cancer 99:S14-5. 2008
  7. pmc Survival from cancer of the stomach in England and Wales up to 2001
    S Rao
    Department of Medicine, Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, UK
    Br J Cancer 99:S19-20. 2008
  8. pmc Docetaxel combined with irinotecan or 5-fluorouracil in patients with advanced oesophago-gastric cancer: a randomised phase II study
    A Roy
    Department of Medicine, Royal Marsden Hospital, Sutton, London, SM25PT, UK
    Br J Cancer 107:435-41. 2012
  9. pmc Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer
    S Rao
    Department of Medicine, Royal Marsden Hospital, Surrey, UK
    Br J Cancer 99:868-74. 2008
  10. pmc A phase II trial of preoperative chemotherapy with epirubicin, cisplatin and capecitabine for patients with localised gastro-oesophageal junctional adenocarcinoma
    N Starling
    Department of Medicine, Royal Marsden Hospital NHS Foundation Trust, Sutton, Surrey, UK
    Br J Cancer 100:1725-30. 2009

Detail Information

Publications115 found, 100 shown here

  1. ncbi request reprint Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer
    Ian Chau
    Department of Medicine, Royal Marsden Hospital, London, United Kingdom
    J Clin Oncol 24:668-74. 2006
    ..To evaluate neoadjuvant capecitabine/oxaliplatin before chemoradiotherapy (CRT) and total mesorectal excision (TME) in newly diagnosed patients with magnetic resonance imaging (MRI) -defined poor-risk rectal cancer...
  2. doi request reprint Capecitabine and oxaliplatin for advanced esophagogastric cancer
    David Cunningham
    Royal Marsden Hospital National Health Service Foundation Trust, Surrey and London, United Kingdom
    N Engl J Med 358:36-46. 2008
    ..We evaluated capecitabine (an oral fluoropyrimidine) and oxaliplatin (a platinum compound) as alternatives to infused fluorouracil and cisplatin, respectively, for untreated advanced esophagogastric cancer...
  3. doi request reprint Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer
    Naureen Starling
    Department of Medicine, Royal Marsden Hospital, Downs Rd, Sutton, Surrey SM2 5PT, United Kingdom
    J Clin Oncol 27:5499-505. 2009
    ....
  4. doi request reprint Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial
    Yu Jo Chua
    Department of Medicine, Royal Marsden Hospital, Sutton, Surrey, UK
    Lancet Oncol 11:241-8. 2010
    ....
  5. pmc Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial
    Tom Waddell
    The Royal Marsden NHS Foundation Trust, London and Surrey, UK
    Lancet Oncol 14:481-9. 2013
    ..We aimed to assess addition of the anti-EGFR antibody panitumumab to epirubicin, oxaliplatin, and capecitabine (EOC) in patients with advanced oesophagogastric adenocarcinoma...
  6. pmc Survival from cancer of the oesophagus in England and Wales up to 2001
    S Rao
    Department of Medicine, Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, UK
    Br J Cancer 99:S14-5. 2008
  7. pmc Survival from cancer of the stomach in England and Wales up to 2001
    S Rao
    Department of Medicine, Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, UK
    Br J Cancer 99:S19-20. 2008
  8. pmc Docetaxel combined with irinotecan or 5-fluorouracil in patients with advanced oesophago-gastric cancer: a randomised phase II study
    A Roy
    Department of Medicine, Royal Marsden Hospital, Sutton, London, SM25PT, UK
    Br J Cancer 107:435-41. 2012
    ..This randomised phase II study evaluated the efficacy and toxicity profile of two non-platinum docetaxel-based doublet regimens in advanced oesophago-gastric cancer...
  9. pmc Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer
    S Rao
    Department of Medicine, Royal Marsden Hospital, Surrey, UK
    Br J Cancer 99:868-74. 2008
    ..At the doses evaluated in serial skin biopsies, matuzumab decreased phosphorylation of EGFR and MAPK, and increased phosphorylation of STAT-3...
  10. pmc A phase II trial of preoperative chemotherapy with epirubicin, cisplatin and capecitabine for patients with localised gastro-oesophageal junctional adenocarcinoma
    N Starling
    Department of Medicine, Royal Marsden Hospital NHS Foundation Trust, Sutton, Surrey, UK
    Br J Cancer 100:1725-30. 2009
    ..Although associated with a low pCR rate, survival with ECX was comparable with published studies suggesting that pCR may not correlate with satisfactory outcome from preoperative chemotherapy for localised oesophageal adenocarcinoma...
  11. pmc Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial
    A Okines
    Department of Medicine, The Royal Marsden Hospital NHS Foundation Trust, Sutton, Surrey, UK
    Br J Cancer 101:1033-8. 2009
    ..Complete resection of metastases can result in cure for selected patients with metastatic colorectal cancer...
  12. pmc Defining patient outcomes in stage IV colorectal cancer: a prospective study with baseline stratification according to disease resectability status
    D J Watkins
    Department of Medicine, Royal Marsden Hospital, London and Surrey, UK
    Br J Cancer 102:255-61. 2010
    ..In a phase II study primarily designed to assess the efficacy of capecitabine and oxaliplatin, we were able to prospectively examine the outcomes of patients with stage IV colorectal cancer according to the baseline resectability status...
  13. pmc Correlation of bevacizumab-induced hypertension and outcome in the BOXER study, a phase II study of capecitabine, oxaliplatin (CAPOX) plus bevacizumab as peri-operative treatment in 45 patients with poor-risk colorectal liver-only metastases unsuitable fo
    A Dewdney
    Department of Medicine, Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, UK
    Br J Cancer 106:1718-21. 2012
    ..The development of bevacizumab-induced arterial hypertension has recently been suggested as a potential predictive biomarker...
  14. doi request reprint Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial
    David Cunningham
    Royal Marsden Hospital, London, UK Electronic address
    Lancet Oncol 14:1077-85. 2013
    ..We aimed to assess the efficacy and safety of bevacizumab plus capecitabine compared with capecitabine alone in elderly patients with metastatic colorectal cancer...
  15. doi request reprint Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles
    David Cunningham
    Royal Marsden NHS Foundation Trust, London and Surrey, UK
    Lancet 381:1817-26. 2013
    ..We investigated whether this survival benefit from dose intensification persists in the presence of rituximab (R-CHOP) in all age groups...
  16. pmc Targeting the PI3K-AKT-mTOR signaling network in cancer
    Khurum H Khan
    The Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK
    Chin J Cancer 32:253-65. 2013
    ....
  17. pmc Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer
    D Cunningham
    Medical Oncology, Royal Marsden Hospital, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK
    Br J Cancer 108:493-502. 2013
    ..Bevacizumab is an anti-VEGF-A monoclonal antibody with clinical benefit in previously treated metastatic colorectal cancer (mCRC)...
  18. pmc Are we ready to stratify treatment for diffuse large B-cell lymphoma using molecular hallmarks?
    Sarah Barton
    Department of Medicine, Royal Marsden Hospital, Downs Road, Sutton, Surrey, SM2 5PT, UK
    Oncologist 17:1562-73. 2012
    ..This review examines emerging molecular targets and novel therapeutic agents in DLBCL, and discusses whether stratifying therapy for DLBCL using molecular features is merited by current preclinical and clinical evidence...
  19. pmc Gemcitabine based combination chemotherapy in advanced pancreatic cancer-indirect comparison
    Asma Sultana
    CRUK Liverpool Cancer Trials Unit, Cancer Research Centre, 200 London Road, Liverpool L3 9TA, UK
    BMC Cancer 8:192. 2008
    ..There is paucity of evidence in the form of direct head-to-head randomised controlled trials to determine which combinations are to be preferred...
  20. doi request reprint Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer
    David Cunningham
    Royal Marsden National HealthService NHS Foundation Trust, London and Surrey, United Kingdom
    J Clin Oncol 27:5513-8. 2009
    ..This open-label study was designed to compare the overall survival (OS) of patients randomly assigned to GEM alone or GEM plus capecitabine (GEM-CAP)...
  21. ncbi request reprint Adjuvant chemotherapy of colorectal cancer
    David Cunningham
    Department of Medicine, Royal Marsden Hospital, Sutton, Surrey SM2 5PT, UK
    Lancet 370:1980-1. 2007
  22. doi request reprint Rechallenge with platinum plus fluoropyrimidine +/- epirubicin in patients with oesophagogastric cancer
    A F C Okines
    Department of Medicine, The Royal Marsden Hospital, London, UK
    Oncology 79:150-8. 2010
    ..The aim of this retrospective study was to evaluate survival following rechallenge with platinum plus fluoropyrimidine (PF) +/- epirubicin...
  23. doi request reprint Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer
    D Cunningham
    Department of Medicine, Royal Marsden Hospital, London and Surrey, UK
    Ann Oncol 20:244-50. 2009
    ..The aim of this multicentre, open-label, phase IIIb study was to assess the addition of oxaliplatin to two different 5-FU regimens...
  24. doi request reprint Colorectal cancer
    David Cunningham
    Gastrointestinal Unit, Royal Marsden Hospital National Health Service Foundation Trust, London and Surrey, UK
    Lancet 375:1030-47. 2010
    ..However, biomarker development is essential to aid selection of patients likely to respond to therapy, thereby rationalising treatments and improving outcomes...
  25. ncbi request reprint Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer
    David Cunningham
    Department of Medicine, Royal Marsden Hospital, Sutton, Surrey, United Kingdom
    N Engl J Med 355:11-20. 2006
    ..We assessed whether the addition of a perioperative regimen of ECF to surgery improves outcomes among patients with potentially curable gastric cancer...
  26. doi request reprint Thromboembolism in patients with advanced gastroesophageal cancer treated with anthracycline, platinum, and fluoropyrimidine combination chemotherapy: a report from the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies Group
    Naureen Starling
    Royal Marsden Hospital National Health Service Foundation Trust, Surrey and London, United Kingdom
    J Clin Oncol 27:3786-93. 2009
    ..Data concerning the prevalence of and outcomes related to thromboembolic events (TEs) in patients with advanced gastroesophageal cancer who are undergoing chemotherapy are limited...
  27. doi request reprint Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C)
    Alice Dewdney
    Department of Medicine, Royal Marsden Hospital, Surrey, UK
    J Clin Oncol 30:1620-7. 2012
    ..To evaluate the addition of cetuximab to neoadjuvant chemotherapy before chemoradiotherapy in high-risk rectal cancer...
  28. ncbi request reprint Gemcitabine, cisplatin and methylprednisolone (GEM-P) with or without Rituximab in relapsed and refractory patients with diffuse large B cell lymphoma (DLBCL)
    Bhawna Sirohi
    Lymphoma Unit, Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK
    Hematology 12:149-53. 2007
    ..04). GEM-P is an effective second-line regimen in patients with relapsed or refractory DLBCL and the addition of Rituximab appears to further improve outcomes...
  29. ncbi request reprint Perioperative chemotherapy with or without bevacizumab in patients with metastatic colorectal cancer undergoing liver resection
    Anastasia Constantinidou
    Department of Medicine, Royal Marsden Hospital, London and Surrey, UK
    Clin Colorectal Cancer 12:15-22. 2013
    ..A retrospective review of our patient records showed that the addition of bevacizumab did not increase morbidity or mortality related to liver resection. Pathologic complete response (CR) is associated with prolonged survival...
  30. doi request reprint Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: dose-finding study for the prospective multicenter, randomized, phase II/III REAL-3 trial
    Alicia F C Okines
    Royal Marsden Hospital, London, UK
    J Clin Oncol 28:3945-50. 2010
    ....
  31. doi request reprint Final analysis of the UKLG LY02 trial comparing 6-8 cycles of CHOP with 3 cycles of CHOP followed by a BEAM autograft in patients <65 years with poor prognosis histologically aggressive NHL
    David C Linch
    NCRI UK Lymphoma Group, CRUK and UCL Cancer Trials Centre UCL, London, UK
    Br J Haematol 149:237-43. 2010
    ..0008). In conclusion, no survival benefit was demonstrated for an early autograft in first response...
  32. ncbi request reprint GEM-P chemotherapy is active in the treatment of relapsed Hodgkin lymphoma
    Eliza A Hawkes
    Royal Marsden NHS Foundation Trust, Downs Rd Sutton, Surrey, SM2 5PT, UK
    Ann Hematol 93:827-34. 2014
    ..GEM-P is a salvage chemotherapy with relatively high response rates, leading to successful transplantation in appropriate patients, in the treatment of relapsed or refractory HL. ..
  33. ncbi request reprint Longitudinal quality of life and quality adjusted survival in a randomised controlled trial comparing six months of bolus fluorouracil/leucovorin vs. twelve weeks of protracted venous infusion fluorouracil as adjuvant chemotherapy for colorectal cancer
    Ian Chau
    Department of Medicine, Royal Marsden Hospital, Sutton, Surrey, UK
    Eur J Cancer 41:1551-9. 2005
    ..There was a trend towards better QAS with PVI 5-FU. Twelve weeks of adjuvant PVI 5-FU was associated with significantly better QOL during treatment and faster time to recovery compared to 6 months of bolus 5-FU/LV...
  34. ncbi request reprint Phase III study of mitomycin-C with protracted venous infusion or circadian-timed infusion of 5-fluorouracil in advanced colorectal carcinoma
    Timothy J Price
    Gastrointestinal Unit, Royal Marsden Hospital, London, UK
    Clin Colorectal Cancer 3:235-42. 2004
    ..However, dose intensification of 5-FU using a circadian-timed, flat-rate infusion did not lead to improved response or survival...
  35. ncbi request reprint The value of routine serum carcino-embryonic antigen measurement and computed tomography in the surveillance of patients after adjuvant chemotherapy for colorectal cancer
    Ian Chau
    Department of Medicine, Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, UK
    J Clin Oncol 22:1420-9. 2004
    ..This analysis aims to evaluate routine carcino-embryonic antigen (CEA) and computed tomography (CT) of thorax, abdomen, and pelvis as part of protocol-specified follow-up policy for colorectal cancer (CRC)...
  36. doi request reprint Second cancer risk after chemotherapy for Hodgkin's lymphoma: a collaborative British cohort study
    Anthony J Swerdlow
    Section of Epidemiology, Sir Richard Doll Building, Institute of Cancer Research, Sutton, Surrey SM2 5NG, United Kingdom
    J Clin Oncol 29:4096-104. 2011
    ..We investigated the long-term risk of second primary malignancy after chemotherapy for Hodgkin's lymphoma (HL) in a much larger cohort than any yet published, to our knowledge...
  37. ncbi request reprint A randomized trial comparing defined-duration with continuous irinotecan until disease progression in fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer
    Rohit Lal
    Department of Medicine, Royal Marsden Hospital, Downs Rd, Sutton, Surrey, United Kingdom SM2 5PT
    J Clin Oncol 22:3023-31. 2004
    ..We performed a multicenter phase III trial to compare the two policies of defined-duration versus continuous irinotecan treatment...
  38. doi request reprint Nonsurgical management of esophageal adenocarcinoma
    Dorothy M Gujral
    Gastrointestinal Unit, Royal Marsden Hospital NHS Foundation Trust, Sutton, United Kingdom
    Clin Colorectal Cancer 10:165-70. 2011
    ..To clarify toxicities and outcomes of combined modality treatment, we performed a retrospective review...
  39. ncbi request reprint Capecitabine and streptozocin ± cisplatin in advanced gastroenteropancreatic neuroendocrine tumours
    Tim Meyer
    Neuroendocrine Tumour Unit, The Royal Free Hospital, Pond Street, London, UK UCL Cancer Institute, London, UK
    Eur J Cancer 50:902-11. 2014
    ..The NET01 trial was designed to investigate whether capecitabine combined with streptozocin was an acceptable regimen with or without adding cisplatin...
  40. doi request reprint Use of diagnostic information submitted to the United Kingdom Central Cardiac Audit Database: development of categorisation and allocation algorithms
    Kate L Brown
    Cardiac Unit, Great Ormond Street Hospital NHS Trust, London, United Kingdom
    Cardiol Young 23:491-8. 2013
    ..To categorise records according to primary cardiac diagnosis in the United Kingdom Central Cardiac Audit Database in order to add this information to a risk adjustment model for paediatric cardiac surgery...
  41. doi request reprint Factors affecting survival in patients aged 60 and over with diffuse large B cell lymphoma failing first-line therapy
    Lisa Lowry
    Department of Haematology, University College London, London, UK Cancer Research UK and UCL Cancer Trials Centre, London, UK Electronic address
    J Geriatr Oncol 4:134-40. 2013
    ..Less is known about the survival prospects in older people, if first-line therapy fails. This study aimed to provide additional information regarding prognosis in this group...
  42. ncbi request reprint Stem cell transplantation in Hodgkin lymphoma
    Felicity Murphy
    Royal Marsden NHS Foundation Trust, Sutton, Surrey, SM2 5PT, UK
    Expert Rev Anticancer Ther 7:297-306. 2007
    ..For patients with multiple relapses and chemotherapy refractory disease, novel approaches are necessary...
  43. doi request reprint Evaluating mesorectal lymph nodes in rectal cancer before and after neoadjuvant chemoradiation using thin-section T2-weighted magnetic resonance imaging
    Dow Mu Koh
    Academic Department of Radiology, The Royal Marsden Hospital, Sutton, United Kingdom
    Int J Radiat Oncol Biol Phys 71:456-61. 2008
    ....
  44. ncbi request reprint Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer--pooled analysis from three multicenter, randomized, controlled trials using individual patient data
    Ian Chau
    Department of Medicine, Royal Marsden Hospital, London, Surrey, UK
    J Clin Oncol 22:2395-403. 2004
    ..To identify baseline prognostic factors and assess whether pretreatment quality of life (QoL) predicts survival in patients with locally advanced or metastatic esophago-gastric cancer...
  45. doi request reprint Docetaxel and irinotecan as second-line therapy for advanced oesophagogastric cancer
    Eliza Hawkes
    The Royal Marsden Hospital, London and Surrey, UK
    Eur J Cancer 47:1146-51. 2011
    ..Docetaxel combined with irinotecan (DI) provides a suitable option due to the lack of cross-reactivity with first-line therapeutics and a tolerable toxicity profile...
  46. ncbi request reprint Chemotherapy for advanced pancreatic cancer
    Yu Jo Chua
    Department of Medicine, Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, UK
    Best Pract Res Clin Gastroenterol 20:327-48. 2006
    ..This article will review and discuss the clinical trials of chemotherapy for this disease, including the more recent trials, which have included the novel targeted agents...
  47. pmc Peri-operative chemotherapy in the management of resectable colorectal cancer pulmonary metastases
    Eliza A Hawkes
    Department of Medicine, Royal Marsden Hospital, Sutton, Surrey, UK SM2 5PT
    BMC Cancer 12:326. 2012
    ..Surgery is often advocated in patients with resectable pulmonary metastases from colorectal cancer (CRC). Our study aims to evaluate peri-operative chemotherapy in patients with metastastic CRC undergoing pulmonary metastasectomy...
  48. doi request reprint Breast cancer risk after supradiaphragmatic radiotherapy for Hodgkin's lymphoma in England and Wales: a National Cohort Study
    Anthony J Swerdlow
    Section of Epidemiology, Sir Richard Doll Building, Institute of Cancer Research, Sutton, Surrey SM2 5NG, UK
    J Clin Oncol 30:2745-52. 2012
    ....
  49. doi request reprint Current perspective: bevacizumab in colorectal cancer--a time for reappraisal?
    Alicia Okines
    Department of Medicine, The Royal Marsden Hospital NHS Foundation Trust, Downs Road, Sutton, Surrey SM2 5PT, United Kingdom
    Eur J Cancer 45:2452-61. 2009
    ..Health economics have unfortunately limited the universal use of bevacizumab, but it is hoped that the future identification of predictive biomarkers may enhance the benefits and thereby improve cost-effectiveness...
  50. doi request reprint Longitudinal assessment of quality of life in rectal cancer patients with or without stomas following primary resection
    Thomas Yau
    Royal Marsden Hospital, London and Surrey, United Kingdom
    Dis Colon Rectum 52:669-77. 2009
    ..The purpose of this study was to assess the longitudinal impact of stoma formation on the health-related quality of life of rectal cancer patients treated with adjuvant chemotherapy...
  51. ncbi request reprint Impact of 5-fluorouracil rechallenge on subsequent response and survival in advanced colorectal cancer: pooled analysis from three consecutive randomized controlled trials
    Cheng Yeoh
    Department of Medicine, Royal Marsden Hospital, London and Surrey, UK
    Clin Colorectal Cancer 3:102-7. 2003
    ....
  52. ncbi request reprint Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial
    Kirit M Ardeshna
    Department of Haematology, University College Hospital, London, UK Electronic address
    Lancet Oncol 15:424-35. 2014
    ..We assessed whether rituximab use could delay the need for chemotherapy or radiotherapy compared with watchful waiting and the effect of this strategy on quality of life (QoL)...
  53. ncbi request reprint Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non-Hodgkin's lymphoma
    Ian Chau
    Department of Medicine, Royal Marsden Hospital, London, UK
    Br J Haematol 120:970-7. 2003
    ..9-80.5%). In conclusion, GEM-P is a novel combination salvage therapy for poor-prognostic primary progressive or multiply relapsed lymphoma patients. It has clinically significant activity with a favourable toxicity profile...
  54. ncbi request reprint Systemic treatment of gastric cancer
    James L B Dickson
    Gastrointestinal Unit, Department of Medicine, Royal Marsden Hospital NHS Trust, London and Surrey, UK
    Eur J Gastroenterol Hepatol 16:255-63. 2004
    ..Newer chemotherapeutic agents, including irinotecan, oxaliplatin and taxanes, show promising activity, and are currently being tested in phase III trials...
  55. doi request reprint Neoadjuvant chemotherapy alone for early-stage rectal cancer: an evolving paradigm?
    Eliza A Hawkes
    Royal Marsden Hospital, London and Surrey, United Kingdom
    Semin Radiat Oncol 21:196-202. 2011
    ..This review discusses the current data and feasibility of managing early stage rectal cancer with neoadjuvant chemotherapy before surgical resection...
  56. ncbi request reprint Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study
    Anthony J Swerdlow
    Section of Epidemiology, Sir Richard Doll Building, Institute of Cancer Research, Sutton, Surrey SM2 5NG, UK
    J Natl Cancer Inst 99:206-14. 2007
    ....
  57. doi request reprint Correlation of overall survival with gene expression profiles in a prospective study of resectable esophageal cancer
    Sheela Rao
    Royal Marsden Hospital, London and Surrey, UK
    Clin Colorectal Cancer 10:48-56. 2011
    ..This prospective study was designed to correlate gene expression profiles with clinical outcome in this setting...
  58. ncbi request reprint Pharmacotherapy for oesophagogastric cancer
    Christopher Jackson
    Gastrointestinal and Lymphoma Units, Royal Marsden Hospital, London and Surrey, United Kingdom
    Drugs 67:2539-56. 2007
    ..We examine areas of current research and highlight future therapeutic directions...
  59. ncbi request reprint Mucosa associated lymphoid tissue lymphoma of the lung: the Royal Marsden Hospital experience
    Hendrik Tobias Arkenau
    Department of Medicine, Royal Marsden Hospital, London, UK
    Leuk Lymphoma 48:547-50. 2007
    ....
  60. ncbi request reprint Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
    David Cunningham
    Royal Marsden Hospital, London, United Kingdom
    N Engl J Med 351:337-45. 2004
    ..We compared the efficacy of cetuximab in combination with irinotecan with that of cetuximab alone in metastatic colorectal cancer that was refractory to treatment with irinotecan...
  61. doi request reprint Where to position monoclonal antibodies in first-line treatment of advanced colorectal cancer
    Christopher Jackson
    Gastrointestinal and Lymphoma Units, Royal Marsden Hospital London and Surrey, Downs Road, Sutton, Surrey, United Kingdom
    Eur J Cancer 44:652-62. 2008
    ....
  62. ncbi request reprint Cetuximab in previously treated colorectal cancer
    Naureen Starling
    Royal Marsden Hospital, Downs Road, Sutton, Surrey, United Kingdom
    Clin Colorectal Cancer 5:S28-33. 2005
    ..This review discusses the development of cetuximab in pretreated CRC to date and future directions with this novel therapy...
  63. ncbi request reprint Multicenter randomized phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin in inoperable pancreatic cancer
    Nick Maisey
    Royal Marsden Hospital, Surrey, United Kingdom
    J Clin Oncol 20:3130-6. 2002
    ..To compare protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin (MMC) in patients with advanced pancreatic cancer in a multicenter, prospectively randomized study...
  64. pmc Inflammatory (B) symptoms are independent predictors of myelosuppression from chemotherapy in Non-Hodgkin Lymphoma (NHL) patients--analysis of data from a British National Lymphoma Investigation phase III trial comparing CHOP to PMitCEBO
    Rohini Sharma
    1Imperial College, London, UK
    BMC Cancer 9:153. 2009
    ..We investigated whether B symptoms were associated with greater toxicity in patients treated for non-Hodgkin lymphoma (NHL)...
  65. ncbi request reprint Non-operative treatment after neoadjuvant chemoradiotherapy for rectal cancer
    Brian D P O'Neill
    Department of Clinical Oncology, Royal Marsden Hospital, Sutton, Surrey, UK
    Lancet Oncol 8:625-33. 2007
    ....
  66. doi request reprint The unique entity of nodular lymphocyte-predominant Hodgkin lymphoma: current approaches to diagnosis and management
    Eliza A Hawkes
    Royal Marsden Hospital, London and Surrey, UK
    Leuk Lymphoma 53:354-61. 2012
    ..Options for treatment include radiotherapy, chemotherapy or combined chemotherapy plus radiotherapy and targeted anti-CD20 antibody therapy, as well as observation in selected patients...
  67. ncbi request reprint Thymidylate synthase expression in advanced colorectal cancer predicts for response to raltitrexed
    David C Farrugia
    Section of Medicine and Cancer Research UK Centre for Cancer Therapeutics, Institute of Cancer Research, Sutton, Surrey SM2 5NG, United Kingdom
    Clin Cancer Res 9:792-801. 2003
    ..The purpose of this research was to evaluate the predictive value of expression of thymidylate synthase (TS) and other genes for response to raltitrexed (RTX)...
  68. ncbi request reprint Adjuvant treatment for resectable pancreatic cancer
    Yu Jo Chua
    Department of Medicine, Royal Marsden Hospital, Downs Rd, Sutton, Surrey SM2 5PT, United Kingdom
    J Clin Oncol 23:4532-7. 2005
    ..The optimal chemotherapy regimen for use as adjuvant treatment is the subject of ongoing trials. Other strategies which should be explored include neoadjuvant treatment and the incorporation of novel targeted agents into management...
  69. doi request reprint Timing of surgery following preoperative therapy in rectal cancer: the need for a prospective randomized trial?
    Jessica Evans
    1 Departments of Surgery and Radiology, Royal Marsden Hospital, London, United Kingdom
    Dis Colon Rectum 54:1251-9. 2011
    ..In rectal cancer, the standard of care after the completion of radiotherapy is surgery at 6 to 8 weeks. However, there is variation regarding the timing of surgery...
  70. ncbi request reprint Site of relapse after chemotherapy alone for stage I and II Hodgkin's disease
    Mehdi Shahidi
    Academic Department of Radiotherapy and Oncology, The Royal Marsden NHS Trust and Institute of Cancer Research, Sutton, UK
    Radiother Oncol 78:1-5. 2006
    ..There is yet no consensus regarding the appropriate radiotherapy portal following chemotherapy. A good guide to the adjuvant radiotherapy field is the site of relapse in patients treated with chemotherapy alone...
  71. ncbi request reprint Neoadjuvant treatment of unresectable liver metastases from colorectal cancer
    Yu Jo Chua
    Department of Medicine, Royal Marsden Hospital, Surrey and London, United Kingdom
    Clin Colorectal Cancer 5:405-12. 2006
    ....
  72. ncbi request reprint Recent data with anti-epidermal growth factor receptor antibodies and irinotecan in colon cancer
    Yu Jo Chua
    Department of Medicine, Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, UK
    Clin Colorectal Cancer 5:S81-8. 2005
    ..This article reviews the recent evidence supporting the combination of these anti-EGFR agents with the cytotoxic chemotherapeutic agent irinotecan...
  73. ncbi request reprint Therapeutic options in gastric cancer: neoadjuvant chemotherapy vs postoperative chemoradiotherapy
    Christopher Jackson
    Gastrointestinal and Lymphoma Unit, Royal Marsden Hospital, Sutton, Surrey, United Kingdom
    Oncology (Williston Park) 21:1084-7; discussion 1090, 1096-8, 1101. 2007
    ..These trials demonstrated statistically significant survival benefits in patients with resectable gastric cancer. This review will consider these trials and their implications for clinical practice...
  74. doi request reprint Efficacy of palliative low-dose involved-field radiation therapy in advanced lymphoma: a phase II study
    Vedang Murthy
    Academic Unit of Radiotherapy and Oncology, The Royal Marsden NHS Foundation Trust, Surrey, UK
    Clin Lymphoma Myeloma 8:241-5. 2008
    ..To confirm the efficacy of low-dose involved-field radiation therapy (LD-IFRT) as palliative treatment in patients symptomatic from advanced lymphoma...
  75. pmc Selecting patients with locally advanced rectal cancer for neoadjuvant treatment strategies
    Alice Dewdney
    Department of Medicine, Royal Marsden Hospital, London and Surrey, UK
    Oncologist 18:833-42. 2013
    ....
  76. ncbi request reprint Retrospective study of resection of pulmonary metastases in patients with advanced colorectal cancer: the development of a preoperative chemotherapy strategy
    Francesca Negri
    Department of Medicine, Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, U K
    Clin Colorectal Cancer 4:101-6. 2004
    ..Moreover, preoperative chemotherapy produced a high response rate, with no patients experiencing disease progression before surgery...
  77. ncbi request reprint The frequency and pattern of cardiotoxicity observed with capecitabine used in conjunction with oxaliplatin in patients treated for advanced colorectal cancer (CRC)
    Matthew Ng
    Department of Medicine, Royal Marsden Hospital, Sutton, Surrey, UK
    Eur J Cancer 41:1542-6. 2005
    ..Patients with ischaemic heart disease appeared to be at increased risk. Physicians and patients need to be aware of these complications, so that prompt discontinuation of treatment and appropriate interventions may be instituted...
  78. doi request reprint Preoperative and postoperative chemotherapy for gastric cancer
    Vikram K Jain
    Department of Medicine, Royal Marsden Hospital, Down s Road, Sutton, Surrey SM2 5PT, UK
    Surg Oncol Clin N Am 21:99-112. 2012
    ..Regardless of these variations, systemic chemotherapy consistently results in a survival benefit when used in multimodality treatment of operable gastric cancer...
  79. ncbi request reprint The role of epidermal growth factor receptor-targeted antibody therapy in previously treated colorectal cancer
    David Watkins
    Department of Medicine, Royal Marsden Hospital, Sutton, Surrey, United Kingdom
    Clin Colorectal Cancer 6:S47-52. 2007
    ..In this article, we review the clinical development of EGFR-targeted therapies and discuss their current role in the management of patients with previously treated advanced CRC...
  80. ncbi request reprint Sixty-day all-cause mortality rates in patients treated for gastrointestinal cancers, in randomised trials, at the Royal Marsden Hospital
    Ourania Katopodis
    Gastrointestinal Unit, Royal Marsden Hospital, Downs Road, Sutton SM2 5PT, UK
    Eur J Cancer 40:2230-6. 2004
    ..In adjuvant colorectal cancer, one patient died within 60 days (myocardial infarction). This study provides a benchmark for assessing the safety of regimens used in these disease settings...
  81. ncbi request reprint The role of cetuximab in the therapy of previously treated advanced colorectal cancer
    Geoff Chong
    Royal Marsden Hospital, London and Surrey, United Kingdom
    Semin Oncol 32:S55-8. 2005
    ....
  82. pmc Targeting angiogenesis in esophagogastric adenocarcinoma
    Alicia F C Okines
    The Royal Marsden Hospital NHS Foundation Trust London and Surrey, Surrey, UK
    Oncologist 16:844-58. 2011
    ..We are therefore currently unable to personalize antiangiogenic therapy for established indications, or use molecular selection for clinical trials evaluating novel indications...
  83. doi request reprint Capecitabine in gastric cancer
    Alicia Okines
    Royal Marsden Hospital, London and Surrey, UK
    Drugs Today (Barc) 44:629-40. 2008
    ....
  84. ncbi request reprint Chemotherapy in colorectal cancer: new options and new challenges
    Ian Chau
    Gastrointestinal Unit, Department of Medicine, Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, UK
    Br Med Bull 64:159-80. 2002
    ..This review will focus on the place of chemotherapy in colorectal cancer, but not its role in combination with radiotherapy in rectal cancer...
  85. doi request reprint Targeted therapy for gastric cancer
    Elizabeth C Smyth
    Royal Marsden Hospital, Downs Road, Surrey, SM2 5PT, UK
    Curr Treat Options Oncol 13:377-89. 2012
    ..It is hoped that treatment of patients in such molecularly defined groups is will lead to significant gains in survival compared to current treatment paradigms...
  86. ncbi request reprint Current treatment strategies in elderly patients with metastatic colorectal cancer
    Hendrik Tobias Arkenau
    Department of Medical Oncology, Royal Marsden Hospital London and Sutton, Surrey, United Kingdom
    Clin Colorectal Cancer 6:508-15. 2007
    ..This article reviews the development of treatment for elderly patients with metastatic CRC, from single-agent fluoropyrimidines to combination therapies...
  87. ncbi request reprint Potential of surface-coil MRI for staging of esophageal cancer
    Angela M Riddell
    Department of Diagnostic Radiology, The Royal Marsden Hospital, Downs Road, Sutton, Surrey, London, United Kingdom, SM2 5PT
    AJR Am J Roentgenol 187:1280-7. 2006
    ..The aim of this pilot study was to assess the feasibility of external surface-coil MRI as a new method of imaging the esophagus and esophageal cancer...
  88. doi request reprint Targeting the human EGFR family in esophagogastric cancer
    Alicia Okines
    Department of Medicine, Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, UK
    Nat Rev Clin Oncol 8:492-503. 2011
    ..We discuss the preclinical rationale for targeting human EGFRs and recent clinical reports of these targeted agents in esophagogastric cancer...
  89. ncbi request reprint Monoclonal antibodies against vascular endothelial growth factor and epidermal growth factor receptor in advanced colorectal cancers: present and future directions
    Naureen Starling
    Department of Medicine, Royal Marsden Hospital, Sutton, Surrey, UK
    Curr Opin Oncol 16:385-90. 2004
    ..Monoclonal antibodies against important tumorigenic targets have been in development for over a decade. Recently, cetuximab and bevacizumab have generated significant interest and are the focus of this review...
  90. doi request reprint Epidermal growth factor receptor inhibitor-related skin toxicity: mechanisms, treatment, and its potential role as a predictive marker
    Diletta Bianchini
    Department of Medicine, Royal Marsden Hospital, Down s Road, Sutton, Surrey, SM2 5PT UK
    Clin Colorectal Cancer 7:33-43. 2008
    ..This review aims to summarize and update the current knowledge of the clinical presentation, predictive and prognostic value, and the management of EGFRI-related skin toxicity...
  91. ncbi request reprint Insulin-like growth factor 1 receptor targeted therapeutics: novel compounds and novel treatment strategies for cancer medicine
    Madeleine Hewish
    Department of Medicine, Royal Marsden Hospital, London and Surrey, UK
    Recent Pat Anticancer Drug Discov 4:54-72. 2009
    ..are included where appropriate. We then outline the current understanding of toxicity related to IGF-1R targeted therapy, and finally outline areas for further research...
  92. ncbi request reprint Panitumumab
    Yu Jo Chua
    Department of Medicine, Royal Marsden Hospital, London and Surrey, UK
    Drugs Today (Barc) 42:711-9. 2006
    ..Clinical trial results in colorectal cancer, in which the development of this agent is most advanced, will also be discussed, as will the rash associated with treatment...
  93. ncbi request reprint Adjuvant therapy in colon cancer: current status and future directions
    Ian Chau
    Gastrointestinal Unit, Department of Medicine, Royal Marsden Hospital, Downs Road, Sutton SM2 5PT, UK
    Cancer Treat Rev 28:223-36. 2002
    ..This review summarises the current status of adjuvant therapy in colon cancer and describes the future directions for research...
  94. ncbi request reprint Capecitabine in advanced gastric cancer
    Alicia Okines
    Royal Marsden Hospital, London and Surrey, UK
    Expert Opin Pharmacother 8:2851-61. 2007
    ..Future trials evaluating biologicals are now incorporating capecitabine combinations as control arms in both advanced disease and peri-operative settings in gastric cancer...
  95. ncbi request reprint The role of preoperative chemotherapy for esophageal cancer: when is surgery alone feasible?
    Geoff Chong
    Royal Marsden Hospital, London, UK
    Nat Clin Pract Oncol 2:172-3. 2005
  96. ncbi request reprint Gemcitabine and its combinations in the treatment of malignant lymphoma
    Ian Chau
    Department of Medicine, Royal Marsden Hospital, Sutton, Surrey, United Kingdom
    Clin Lymphoma 3:97-104. 2002
    ..However, as gemcitabine has not been evaluated in randomized studies either alone or in combination with other chemotherapy drugs, its exact role in the treatment paradigm of lymphoma remains to be determined...
  97. ncbi request reprint The palatability of milk-based and non-milk-based nutritional supplements in gastrointestinal cancer and the effect of chemotherapy
    Zahra Rahemtulla
    Imperial College Faculty of Medicine, Chelsea and Westminster Hospital, London, UK
    Clin Nutr 24:1029-37. 2005
    ..Oral nutritional supplements may have a role in the management of weight loss in patients with cancer. Information on preference for different types of nutritional supplements and the influence of taste changes and chemotherapy is limited...
  98. ncbi request reprint Patterns of elevation of plasma 2'-deoxyuridine, a surrogate marker of thymidylate synthase (TS) inhibition, after administration of two different schedules of 5-fluorouracil and the specific TS inhibitors raltitrexed (Tomudex) and ZD9331
    Hugo E R Ford
    Cancer Research Campaign Centre for Cancer Therapeutics at the Institute of Cancer Research and Royal Marsden National Health Service Trust, Sutton, Surrey, SM2 5NG
    Clin Cancer Res 8:103-9. 2002
    ..This suggests that the mechanism of antiproliferative toxicity from bolus 5-FU/LV is partly non-TS mediated. These results clarify underlying pharmacodynamic processes and could guide scheduling of 5-FU and TS inhibitors...
  99. ncbi request reprint Overview of preoperative and postoperative therapy for colorectal cancer: the European and United States perspectives
    Ian Chau
    Gastrointestinal Unit, Department of Medicine, Royal Marsden Hospital, London and Surrey, UK
    Clin Colorectal Cancer 3:19-33. 2003
    ....
  100. ncbi request reprint Second-line therapy for advanced colorectal carcinoma
    Naureen Starling
    Gastrointestinal and Lymphoma Units, Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, UK
    Curr Oncol Rep 7:173-80. 2005
    ....
  101. ncbi request reprint Clinical and molecular prognostic factors in patients with metastatic colorectal cancer treated with 5-fluorouracil-based chemotherapy
    Robin L Jones
    Gastrointestinal Unit, Royal Marsden Hospital, Sutton, Surrey, United Kingdom
    Clin Colorectal Cancer 2:235-8. 2003